Post-streptococcal uveitis syndrome in a Caucasian population: a case series.
Adalimumab
/ therapeutic use
Adolescent
Anti-Inflammatory Agents
/ therapeutic use
Child
Child, Preschool
Female
Humans
Immunosuppressive Agents
/ therapeutic use
Male
Retrospective Studies
Streptococcal Infections
/ complications
Syndrome
Treatment Outcome
Uveitis
/ etiology
Vitreous Body
/ microbiology
White People
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
24
04
2018
accepted:
22
08
2018
pubmed:
20
9
2018
medline:
23
8
2019
entrez:
20
9
2018
Statut:
ppublish
Résumé
Uveitis is an uncommon manifestation of post-streptococcal syndrome (PSUS). Despite reports, the condition is often not well recognised. The purpose of this study is to report a case series of children with post-streptococcal uveitis. In this retrospective case series, all cases of PSUS were identified from all new paediatric patients diagnosed with uveitis over a 6-year period. Diagnosis of PSUS was based on the following diagnostic criteria: unilateral or bilateral uveitis with positive anti-streptolysin O titres (ASOT) or anti-deoxyribonuclease (anti-DNase) titres, and negative routine investigations for other causes of uveitis. Eleven Caucasian paediatric patients were diagnosed with PSUS. One had a novel finding of peripheral corneal endotheliopathy, 73% of patients presented in spring or winter months and 88% of eyes had a final VA of better than or equal to 6/12 at a mean follow-up of 22 months. Systemic immunosuppressant treatment was used in 36% of patients. Adalimumab was used in 18% of patient's refractory to other treatment. We report on the largest consecutive series of Caucasian patients under 16 years of age with PSUS. We have demonstrated a seasonal preponderance with presentation typically in winter or spring. We report a novel finding of corneal endotheliopathy in one of our PSUS patients. We also report on the benefit of adalimumab in the management of severe cases of PSUS; use of biologics in this particular cohort of uveitis patients has not previously been reported. With aggressive treatment our patients achieved good visual outcomes comparable to other published series.
Sections du résumé
BACKGROUND/OBJECTIVES
Uveitis is an uncommon manifestation of post-streptococcal syndrome (PSUS). Despite reports, the condition is often not well recognised. The purpose of this study is to report a case series of children with post-streptococcal uveitis.
SUBJECTS/METHODS
In this retrospective case series, all cases of PSUS were identified from all new paediatric patients diagnosed with uveitis over a 6-year period. Diagnosis of PSUS was based on the following diagnostic criteria: unilateral or bilateral uveitis with positive anti-streptolysin O titres (ASOT) or anti-deoxyribonuclease (anti-DNase) titres, and negative routine investigations for other causes of uveitis.
RESULTS
Eleven Caucasian paediatric patients were diagnosed with PSUS. One had a novel finding of peripheral corneal endotheliopathy, 73% of patients presented in spring or winter months and 88% of eyes had a final VA of better than or equal to 6/12 at a mean follow-up of 22 months. Systemic immunosuppressant treatment was used in 36% of patients. Adalimumab was used in 18% of patient's refractory to other treatment.
CONCLUSIONS
We report on the largest consecutive series of Caucasian patients under 16 years of age with PSUS. We have demonstrated a seasonal preponderance with presentation typically in winter or spring. We report a novel finding of corneal endotheliopathy in one of our PSUS patients. We also report on the benefit of adalimumab in the management of severe cases of PSUS; use of biologics in this particular cohort of uveitis patients has not previously been reported. With aggressive treatment our patients achieved good visual outcomes comparable to other published series.
Identifiants
pubmed: 30228367
doi: 10.1038/s41433-018-0214-0
pii: 10.1038/s41433-018-0214-0
pmc: PMC6460694
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Immunosuppressive Agents
0
Adalimumab
FYS6T7F842
Types de publication
Journal Article
Langues
eng
Pagination
380-384Références
Am J Ophthalmol. 1999 Mar;127(3):346-7
pubmed: 10088750
Clin Microbiol Rev. 2000 Jul;13(3):470-511
pubmed: 10885988
Optometry. 2000 Apr;71(4):233-8
pubmed: 10974922
Laryngoscope. 2002 Apr;112(4):658-60
pubmed: 12150519
Clin Rheumatol. 2002 Nov;21(6):533-5
pubmed: 12447642
Optom Vis Sci. 2004 Aug;81(8):578-85
pubmed: 15300115
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Ophthalmology. 2006 Apr;113(4):701-6
pubmed: 16581431
Pathology. 2006 Apr;38(2):152-6
pubmed: 16581656
Acta Ophthalmol Scand. 2006 Jun;84(3):424-8
pubmed: 16704712
Clin Infect Dis. 2007 Oct 1;45(7):853-62
pubmed: 17806049
Eye (Lond). 2009 Apr;23(4):985-7
pubmed: 18049487
J Clin Microbiol. 2008 Jul;46(7):2359-67
pubmed: 18463210
J Clin Microbiol. 2009 Apr;47(4):1155-65
pubmed: 19158266
Am J Ophthalmol. 1991 Nov 15;112(5):595-6
pubmed: 1951601
Laeknabladid. 1995 Oct;81(10):728-32
pubmed: 20065464
Ann Trop Paediatr. 2010;30(2):153-5
pubmed: 20522303
Br J Ophthalmol. 2012 Jan;96(1):87-9
pubmed: 21427459
Clin Ophthalmol. 2011;5:1257-9
pubmed: 21966196
J Ophthalmic Vis Res. 2011 Oct;6(4):259-69
pubmed: 22454749
Euro Surveill. 2014 May 01;19(17):5-14
pubmed: 24821122
Ocul Immunol Inflamm. 2016 Dec;24(6):607-609
pubmed: 26713592
Ocul Immunol Inflamm. 2018;26(6):978-985
pubmed: 28448723
Am J Ophthalmol. 1995 Oct;120(4):538-9
pubmed: 7573320
Arch Ophthalmol. 1993 Oct;111(10):1324-5
pubmed: 8216009
Am J Ophthalmol. 1997 Feb;123(2):258-60
pubmed: 9186136
Pediatrics. 1998 Jan;101(1 Pt 1):86-8
pubmed: 9417157
Am J Ophthalmol. 1998 Aug;126(2):317-8
pubmed: 9727533